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S182 Oral Presentationsonly one patient received unrelated PBSC (5  10 6 CD34/kg).
GVHD-prophylaxis comprised Cyclosporine A (CSA) and Myco-
phenolate-Mofetil (MMF). MMF (1200 mg/qm) was administered
until d +100 and tapered thereafter. Two patients received MTX in-
stead of MMF.
Results: The early course after HSCT was uneventful. No acute
GHVD was encountered. No infectious or inflammatory flare
ups were observed. The hematological reconstitution with neutro-
phil (d +19 to +26) and platelet engraftment (d +21 to +22) was in
time. Six to 63 (median 36) months after HSCT, 10 patients are
alive and well (91%) with (95-100%) donor chimerism and stable
hematopoiesis. NBT- and DHR-tests are normalized (95-98%).
All active inflammatory and infectious foci are cured. One adult pa-
tient fathered a child after successful HSCT. One adult patient who
had suffered from severe active therapy-refractory bilateral Asper-
gillosis at transplant and had received a MUD CMV negative
PBSC died at day +150 due to pulmonary failure and endogenous
CMV reactivation.
Conclusion: This modified reduced intensity regimen is efficacious
and well-tolerated in both pediatric and adult high-risk CGD-
patients.72
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Objective: The optimal conditioning regimen for hematopoietic
stem cell transplantation (HSCT) in children with primary immuno-
deficiency diseases is currently unknown. Reduced-intensity condi-
tioning (RIC) concepts allow the inclusion of patients with severe
co-morbidities in transplantation concepts. Here we describe our re-
sults using fludarabine-based RIC regimen for the treatment of pe-
diatric patients with primary immunodeficiency.
Methods: Twenty one patients (8 female, 13 male) with primary
immunodeficiency underwent HSCT using RIC regimen.
Median age at HSCT was 28 months (range: 4 months-14
years).The preparative regimen consisted of fludarabine, melpha-
lan and antithymocyte globulin. 8 patients received stem cell
from healthy full HLA-matched siblings, 7 patients from HLA
matched other relative (four patients from parents, two patients
from grand father and one patient from uncle), 3 patient from
their haploidentical parents and 3 patients from unrelated cord
blood. The graft source was bone marrow in 7 patients, periph-
eral blood stem cells in 11 patients and in 3 patients from cord
blood. The primary immunodeficiencies in these children in-
cluded Leukocyte Adhesion Deficiency type one in 11, Wiskott
Aldrich Syndrome in 3, Griscelli syndrome in 2, Familial Eryth-
rophagocytic Lymphohistiocytosis in 2, severe combined immu-
nodeficiency in 1, Chediak-higashi in 1, and primary CD4
deficiency in 1.For graft-versus-host disease (GVHD) prophy-
laxis, we used Cyclosporine and Methylprednisolone.
Results: All patients except one engrafted. At a median follow-up of
3 months (range, 1-32 months), 18 (85.7%) patients are alive with
sustained engraftment and without recurrent infection, one patient
who not engrafted is alive with uncontrolled disease and two patients
died. 7 patients developed grade II-IV acuteGVHDand 2 developed
limited chronic GVHD.
Among the two dead patients, one of them died from acute
GVHD 30 days after transplantation and the other from aspiration
pneumonia 66 days after transplantation which not related to trans-
plantation. These two dead patients received stem cell from their
haploidentical parents.
Conclusions: These data indicate HSCT following RIC regimen
can be used for treatment of primary immunodeficiency with well
tolerance and low transplant related mortality. When a related hap-
loidentical donor is used, the survival rate is lower than that of pa-
tients receiving HSCT from either an HLA-matched related or
a mismatched HLA-unrelated cords.73
PERFORIN DEPENDENT CYTOTOXICITY REGULATES THE IMMUNE RE-
SPONSE IN TRANS: HOWMUCH DONOR CHIMERISM IS ENOUGH TO PRO-
TECT FROM RECURRENT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
(HLH) AFTER HCT?
Terrell, C.1, Zoller, E.1, Jordan, M.B.1,2 1Cincinnati Children’s Hospital
Medical Center, OH; 2Cincinnati Children’s Hospital Medical Center,
OH
Genetic defects of perforin-dependent cytotoxicity underlie
HLH, a disorder of abnormal immune activation. Allogeneic HCT
can provide a definitive cure for HLH because it corrects these
defects. However, HCT may be complicated by the development
of mixed chimerism after transplantation. There continues to be
significant uncertainty regarding the need for repeat HCT in this
situation. Based on the experience of very limited numbers of
patients, it is thought that relatively small amounts of donor
chimerism are sufficient to protect patients from HLH recurrence
post HCT. We have utilized a murine model of HLH to determine
whether normal cytotoxic function in only a fraction of relevant
hematopoietic or immune cells may restore normal immune
regulation.
Perforin deficient (prf-/-) mice were lethally irradiated and
reconstituted with bone marrow from either wild type (WT),
prf-/-, or other immunodeficient donors. In parallel experiments,
WT or prf-/- T cells were transferred into cyclophosphamide condi-
tioned prf-/- mice. After establishment of bone marrow or T cell
grafts, prf-/- mice were challenged with viral infection and their im-
mune responses were quantitated.
Hematopoietic reconstitution of prf-/- mice with WT bone
marrow reestablished a normal pattern of cytokine production, T
cell activation, and antigen presentation after LCMV infection. As
the fraction of WT chimerism dropped below 10%, however, this
pattern reverted to that seen in prf-/- mice. Complementation
studies demonstrated that though NK cells may play a modest role
in controlling the immune response, reconstitution of normal per-
forin expression in T cells was critical (and sufficient) to reestablish
normal immune regulation. Transfer of purified WT CD8 T cells
alone was also sufficient to reconstitute normal immune responses,
if WT T cell engraftment exceeded 10%.
Because reconstitution of normal perforin expression in a minor
fraction (approximately 10%) of relevant cells is sufficient to reestab-
lish normal immune responsiveness in vivo, we conclude that per-
forin-dependent immunoregulation functions in trans, and that
CD8 T cells are the principle cell population exerting this effect.
These data suggest that donor chimerism of .10% should be suffi-
cient to protect patients from HLH recurrence post HCT, particu-
larly if T cells are of donor origin. These studies also suggest
a minimum target for successful gene therapy of HLH.
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ADOPTIVE IMMUNOTHERAPY AFTER UMBILICAL CORD BLOOD (UCB)
TRANSPLANTATION: MANUFACTURING AND ANALYSIS OF CD19-SPE-
CIFIC UCB-DERIVED T-CELLS FROM SCANT NUMBERS OF UCB MONONU-
CLEAR CELLS
Kelly, S.S.1, Singh, H.1, Figliola, M.J.1, Dawson, M.J.1, Maiti, S.1,
Shpall, E.J.2, Champlin, R.E.2, Cooper, L.J.N.1 1University of Texas
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The rapid procurement, lower risk of graft-versus-host-disease
(GvHD), and the ability to undertake transplantation across
HLA disparities make umbilical cord blood (UCB) an attractive
stem-cell source. Adoptive transfer of tumor-specific T cells after
UCB transplantation (UCBT) is constrained by the functionally
naı¨ve UCB T cells and lack of ability to obtain additional cells.
We have previously shown that the specificity of T cells can be
redirected for CD19 using a chimeric antigen receptor (CAR)
independent of major histocompatibility complex. We have identi-
fied a source of clinical-grade UCB that may be used for
manufacturing without having to reduce the cell dose available
for transplantation. In our laboratory, after UCB units are washed
for clinical infusion, the supernatant is refrozen, and contains small
Oral Presentations S183numbers of UCB cells, including T cells. We evaluated the feasi-
bility of generating UCB-derived CD19-specific T cells for clinical
infusion from the T cells in this residual. These T cells were elec-
troporated with CD19RCD28 CAR expressed as a Sleeping Beauty
(SB) transposon and propagated in the presence of IL-2 and IL-21
on g-irradiated CD19+ K562 artificial antigen presenting cells
(aAPC). The electroporated and propagated cells were a population
of CD8+ and CD4+ memory and effector T cells that exhibit
redirected CD19-dependent killing and cytokine production. The
UCB-derived CD19-specific T cells were further analyzed using
a new technology using the NanoString nCounter Analysis System,
a digital technology that is based on direct multiplexed measure-
ment of mRNA and therefore gene expression that offers a high
level of precision and sensitivity from a few number of cells.
This approach to manufacturing CD19-specific T cells and analy-
sis of mRNA expression profiles will be used to generate donor-
derived CD19-specific T cells that can be infused after UCBT as
an approach to enhance the graft-versus-tumor-effect without
increasing GvHD. The relative ease and low cost associated with
production of clinical grade DNA plasmids, electroporation, and
reproducible outgrowth of T cells stablely expressing CAR on
thawed g-irradiated MCB of aAPC, should enable facilities operat-
ing in compliance with cGMP for Phase I/II to implement adop-
tive immunotherapy trials using CAR+ T cells. By using the
scant numbers of residual UCB cells present after washing, we
have identified one potential way to overcome a major barrier to
UCB-derived T-cell therapies.75
IMPACT OF DONOR CHOICE ON PEDIATRIC DAY +100 TRANSPLANT
MORTALITY: THE PBMTC EXPERIENCE 2002-2004
Lehmann, L.E.1,2, Marcin, J.3, Scott, E.3, Ryan, R.5, Haut, P.6,
Schultz, K.4, Taylor, D.D.3 1Dana Farber Cancer Institute, Boston,
MA; 2Children’s Hospital, Boston, MA; 3University of California Davis,
Sacramento, CA; 4BC Children’s Hospital, Vancouver, BC, Canada;
5Children’s Mercy Hospital, Kansas City, MO; 6Riley Children’s Hospital,
Indianapolis, INBackground: A genotypically matched sibling is almost universally
the preferred donor source for pediatric patients undergoing alloge-
neic hematopoietic stem cell transplant (HSCT). Some patients lack-
ing a matched sibling donor will have a matched or mismatched
related donor identified. It is not clear whether in this setting a family
donor is preferable to an unrelated donor. Using the data base of the
Pediatric BoneMarrow Transplant Consortium from 2002-2004 we
evaluated 100 daymortality in 2696 patients\22 years of age receiv-
ing an non-syngeneic HSCT.
Results: The observed 100 day mortality for matched sibling do-
nors (n5 624) was 9.5%, for other matched family donors (n5 41)
12% and for mismatched sibling donors (n5 89) 19%. Univariate
analysis assigning a value of 1 for the 100 day mortality reported
for 939 autologous transplants from this cohort was performed.
There was no difference in mortality seen in patients transplanted
from amatched sibling donor (OR5 1.2,NS) or othermatched fam-
ily donor (OR5 1.6, NS). The use ofmismatched sibling donors and
matched or mismatched unrelated donors resulted in a significant in-
crease in Day 100 mortality (OR5 2.8-4.1, p\0.005). However, in
multivariate analysis incorporating 47 independent variables there
was a trend toward increased mortality as donor disparity increased.
Compared to those undergoing autologous transplant, patients re-
ceiving a transplant from a matched sibling donor had an OR of
2.3 (95% CI, 1.2-4.5), other matched family donor 3.6 (95% CI,
1.2-11.3), mismatched sibling donor 4.5 (95% CI, 2-10.2), matched
unrelated donor 6.4 (95% CI, 3.9-16.6) and mismatched unrelated
donor 7.8 (95% CI, 3-14.5).
Conclusion: When an HLA matched sibling donor is not avail-
able, the differences in acute mortality between alternative donor
options may be outweighed by other donor/patient considerations.
The use of a mismatched sibling donor or unrelated donor com-
pared to a matched family donor may confer an increased risk
that should be considered in the context of individual patient
circumstances.76
EXCELLENT SURVIVAL AFTER MATCHED UNRELATED DONOR STEM
CELL TRANSPLANTATION IN CHRONIC GRANULOMATOUS DISEASE
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A number of reports document the successful role of matched
related donor hematopoietic stem cell transplant (MRDHSCT)
in patients with Chronic Granulomatous Disease (CGD). Less cer-
tain is the safety and efficacy of HSCT from unrelated donors. We
report the use of HSCT in ten children with a matched related do-
nor (MRD) (n5 4) or a matched unrelated donor (MUD) (n5 6).
The median age of our group was 4.7 years (range: 0.9-8.4 years)
with x-linked (n5 8) or autosomal recessive (n5 2) disease over
a 6 year period (2003-2009). Despite treatment with anti-bacterial
and anti-fungal medications and gamma interferon, nine children
had significant clinical infections before transplant including: oste-
omyelitis (n5 2), lung/liver abscess requiring surgical intervention
(n5 3), aspergillus pneumonia (n5 3) and staphylococcus/
B.cepaciae sepsis/shock (n5 2). The conditioning regimen for pa-
tients receiving a MRD product consisted of busulfan(1 mg/kg,
AUC 900 – 1200 mmol/min/L), cyclophosphamide(90 mg/kg) and
cytarabine(2grams/m2). Patients receiving a MUD product were
conditioned with busulfan(1 mg/kg, AUC 900 – 1200 mmol/min/
L), cychlophosphamide(200 mg/kg) and fludarabine(120 mg/m2).
GvHD prophylaxis consisted of cyclosporine and methrotrexate
for MUD recipients and cyclosporine and prednisone for MRD re-
cipients. Campath (anti-CD52) was used to improve engraftment
and prevent aGvHD in all the patients. The median total nucleated
cell dose was 6108/kg. The median time to neutrophil and plate-
let recovery was 18 days (range, 12-40 days) and 16 days (range, 12-
26 days) respectively. The majority of the patients (n5 8) achieved
100% neutrophil engraftment except two (68, 73%) but all have
sustained correction of their neutrophil oxidative burst defect.
Four patients developed grade I aGVHD requiring only topical
treatment. None of the patients developed grade II-IV aGvHD.
There has been no incidence of cGvHD. Among the post trans-
plant morbidities we report: busulfan related seizures (n5 1), BK
hemorrhagic cystitis (n5 1), and bacterial/fungal pneumonia
(n5 2). None of the patients developed organ failure during the
post transplant period. All patients are currently living with follow
up ranging from 42 days to 6 years. In our cohort, the outcome of
MUDSCT is very feasible and equivalent to MRDSCT and should
be considered early in the course of CGD to cure the underlying
neutrophil defect and improve quality of life in the absence of
a MRD.77
PERIPHERAL BLOOD IS THE STEM CELL SOURCE OF CHOICE FOR RE-
DUCED INTENSITY STEM CELL TRANSPLANT IN CHILDREN
Rao, K.1, Adams, S.1, Goulden, N.1, Davies, G.2, Qasim, W.2,
Gaspar, B.2, Webb, D.3, Ancliff, P.3, Amrolia, P.1, Veys, P.1 1Great
Ormond Street Hospital, London, United Kingdom; 2Great Ormond
Street Hospital, London, United Kingdom; 3Great Ormond Street Hospi-
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Reduced intensity conditioning (RIC) enables SCT in children
with pre-existing organ toxicity. However, there are concerns about
mixed chimerism(MC) in the long term that is sometimes not
sufficient for cure. In a cohort of 148 patients undergoing RIC
SCT (Fludarabine 150 mg/m2, Melphalan 140 mg/m2, Campath
1H 0.6-1 mg/kg) we compared chimerism between those who re-
ceived BM (n5 109) Vs PBSC (n5 41). Median age at transplant
was 3.6 years and median follow-up was 4.7 years.The majority
were transplanted for primary immunodeficiency disorders
(n5 120) and donors were MUD (n5 67), mMUD (n5 45), MSD
(n5 17),MFD (n5 14) andmMFD (n5 8). Survival was equivalent,
70% for BMand 75% for PBSC. Incidence of aGVHD$ grade 2 was
higher with PBSC (40% vs 20% for BM) but the incidence of chronic
GVHD was low (10%).
